NewslettersImmunology of Infectious Disease NewsUncategorizedSyneuRx Reaches Target Enrollment in Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)By Justin.choi - April 13, 20220117SyneuRx™ International announced it has completed enrollment for its Phase II clinical trial evaluating the efficacy and safety of SNB01 (‘Pentarlandir’), a novel COVID-19 oral antiviral candidate.[SyneuRx™ International] 6445212 BBBBBBBB items 1 apa 0 default asc 1 174024 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Press Release